{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:00:11Z","timestamp":1780635611713,"version":"3.54.1"},"reference-count":85,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background and Clinical Significance: Advanced-stage and recurrent metastatic endometrial cancer (EC) is a complex and challenging disease with a poor prognosis. Immunotherapy is a promising treatment for advanced and recurrent mismatch repair deficiency (MMRd) EC. Case Presentation: A 57-year-old female patient with stage 2 dedifferentiated EC with MMRd (immunohistochemistry revealed PMS2 loss) and stage 1 renal clear cell carcinoma received neoadjuvant chemotherapy, underwent radical hysterectomy, received adjuvant chemotherapy and radiotherapy, and underwent partial nephrectomy. Disease progression with recurrent metastases to the third rib and T12 + L1 vertebrae was observed by positron emission tomography\u2013computed tomography (PET-CT) in April 2024. She also had concurrent papillary thyroid carcinoma. Genetic testing confirmed sensitivity to dostarlimab-gxly and pembrolizumab, leading to the initiation of pembrolizumab (200 mg Q3W) and lenvatinib (20 mg QD) in June 2024 after spine surgery. Treatment-related skin toxicities prompted a dose reduction to pembrolizumab 100 mg and lenvatinib 10 mg, but persistent discomfort led to lenvatinib discontinuation in December 2024, with symptom improvement. PET-CT in October 2024 revealed significant improvement in metastatic disease, with probable residual malignancy in the left third rib and posterior pleura, whereas recent follow-up PET-CTs in April and November 2025 showed significantly decreased 18F-fluorodeoxyglucose avidity in the spine and ribs compared with prior studies. She was admitted for her 30th Keytruda cycle in February 2026, with stable vital signs, normal tumor markers, and no post-infusion adverse reactions. Conclusions: We present a 57-year-old female patient initially diagnosed with FIGO Stage 2 EC, who subsequently developed distant metastases and was restaged as FIGO Stage 4B recurrent disease. The management of this patient illustrates the multimodal treatment approach and the critical role of molecular subtyping in guiding immunotherapeutic strategies for recurrent advanced EC.<\/jats:p>","DOI":"10.3390\/diagnostics16111703","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:07:52Z","timestamp":1780326472000},"page":"1703","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent Distant Metastatic Endometrial Cancer Treated with Immunotherapy with Pembrolizumab: A Case Report and Literature Review"],"prefix":"10.3390","volume":"16","author":[{"given":"Oi-Yin","family":"Leung","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-0428","authenticated-orcid":false,"given":"Chiu-Hsuan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-068X","authenticated-orcid":false,"given":"Dah-Ching","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"},{"name":"Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Capozzi, V.A., Scarpelli, E., De Finis, A., Rotondella, I., Scebba, D., Gallinelli, A., Montrucchio, C., Martignon, G., Leotta, M., and Ghi, T. (2023). Optimal Management for Stage IVB Endometrial Cancer: A Systematic Review. Cancers, 15.","DOI":"10.3390\/cancers15215123"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2023.05.069","article-title":"The Right Time for Change: A Report on the Heterogeneity of IVB Endometrial Cancer and Improved Risk-Stratification Provided by New 2023 FIGO Staging Criteria","volume":"175","author":"Haight","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113317","DOI":"10.1016\/j.ejca.2023.113317","article-title":"Verification of the Prognostic Precision of the New 2023 FIGO Staging System in Endometrial Cancer Patients\u2014An International Pooled Analysis of Three ESGO Accredited Centres","volume":"193","author":"Schwameis","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.3390\/curroncol30090574","article-title":"An Overview of Endometrial Cancer with Novel Therapeutic Strategies","volume":"30","author":"Kuhn","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding Immunotherapy to First-Line Treatment of Advanced and Metastatic Endometrial Cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ijgc-2022-003675","article-title":"Immunotherapy in Endometrial Cancer","volume":"33","author":"Mahdi","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2022.11.031","article-title":"The Role of Immunotherapy in Advanced and Recurrent MMR Deficient and Proficient Endometrial Carcinoma","volume":"169","author":"Bogani","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_8","first-page":"129","article-title":"Immunotherapy in the Treatment of Advanced or Recurrent Endometrial Cancer","volume":"22","author":"Mazzeo","year":"2024","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14737140.2022.2126356","article-title":"Pembrolizumab as a Single Agent for Patients with MSI-H Advanced Endometrial Carcinoma","volume":"22","author":"Turinetto","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.ogx.0000527579.58363.20","article-title":"Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1\u2013positive Endometrial Cancer: Results from the KEYNOTE-028 Study","volume":"73","author":"Ott","year":"2018","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/OTT.S368050","article-title":"Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab","volume":"16","author":"Durando","year":"2023","journal-title":"OncoTargets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","unstructured":"(2022, September 12). NCCN Uterine Neoplasms. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1473."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2478\/raon-2021-0009","article-title":"Surgical Treatment and Fertility Perservation in Endometrial Cancer","volume":"55","author":"Kovacevic","year":"2021","journal-title":"Radiol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100895","DOI":"10.1016\/j.currproblcancer.2022.100895","article-title":"Novel Approaches for Treatment of Endometrial Carcinoma","volume":"46","author":"Garg","year":"2022","journal-title":"Curr. Probl. Cancer"},{"key":"ref_16","first-page":"CD007585","article-title":"Lymphadenectomy for the Management of Endometrial Cancer","volume":"10","author":"Frost","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jjco\/hyaa071","article-title":"Adjuvant Treatment of Endometrial Cancer Today","volume":"50","author":"Aoki","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104752","DOI":"10.1016\/j.canrad.2025.104752","article-title":"Radiotherapy for Endometrial Cancer: 2025 Update","volume":"29","author":"Chargari","year":"2025","journal-title":"Cancer Radiother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s11864-022-01031-6","article-title":"Contemporary Use of Hormonal Therapy in Endometrial Cancer: A Literature Review","volume":"23","author":"Kailasam","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/1471-0528.17331","article-title":"The Effect of Progestin Therapy in Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis","volume":"130","author":"Birkendahl","year":"2023","journal-title":"BJOG"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mitranovici, M.-I., Chiorean, D.M., Moraru, L., Moraru, R., Caravia, L., Tiron, A.T., Cotoi, T.C., Toru, H.S., and Cotoi, O.S. (2024). Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review. Pharmaceuticals, 17.","DOI":"10.3390\/ph17030311"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4103\/tcmj.tcmj_152_25","article-title":"Prognostic Factors and Survival of Patients with Endometrial Cancer: A 10-Year Retrospective Cohort Study in a Tertiary Referral Center in Northern Taiwan","volume":"38","author":"Bing","year":"2025","journal-title":"Tzu Chi Med. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.tjog.2024.03.019","article-title":"Prognostic Factors and Survival of Endometrial Cancer: An 11-Year Retrospective Cohort Study in Southern Taiwan","volume":"63","author":"Bing","year":"2024","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bing, R.-S., Tsui, W.L., and Ding, D.-C. (2022). The Association between Diabetes Mellitus, High Monocyte\/Lymphocyte Ratio, and Survival in Endometrial Cancer: A Retrospective Cohort Study. Diagnostics, 13.","DOI":"10.3390\/diagnostics13010044"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Centini, G., Colombi, I., Ianes, I., Perelli, F., Ginetti, A., Cannoni, A., Habib, N., Negre, R.R., Martire, F.G., and Raimondo, D. (2025). Fertility Sparing in Endometrial Cancer: Where Are We Now?. Cancers, 17.","DOI":"10.3390\/cancers17010112"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Januszek, S.M., Wita-Popow, B., Kluz, M., Janowska, M., Januszek, R., Wr\u00f3bel, A., Rogowski, A., Malinowski, K.P., Zuzak, T., and Kluz, T. (2021). Risk Factors for Surgical Treatment of Endometrial Cancer Using Traditional and Laparoscopic Methods. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030429"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"24623","DOI":"10.1038\/s41598-024-74840-4","article-title":"Association between Radiation Therapy for Primary Endometrial Cancer and Risk of Second Primary Malignancies: A Retrospective Cohort Study","volume":"14","author":"Wang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_30","first-page":"141","article-title":"Drug Resistance and Combating Drug Resistance in Cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wagner, V.M., and Backes, F.J. (2023). Do Not Forget about Hormonal Therapy for Recurrent Endometrial Cancer: A Review of Options, Updates, and New Combinations. Cancers, 15.","DOI":"10.3390\/cancers15061799"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106399","DOI":"10.1016\/j.jsbmb.2023.106399","article-title":"Global Expression Analysis of Endometrial Cancer Cells in Response to Progesterone Identifies New Therapeutic Targets","volume":"234","author":"Thiel","year":"2023","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16173","DOI":"10.1002\/cam4.6276","article-title":"Should We Abandon Hormonal Therapy in Endometrial Cancer? Outcomes of Recurrent and Metastatic Endometrial Cancer Treated with Systemic Progestins","volume":"12","author":"Kulkarni","year":"2023","journal-title":"Cancer Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101239","DOI":"10.1016\/j.currproblcancer.2025.101239","article-title":"Hormone Replacement Therapy in Endometrial Cancer Survivors: A Retrospective Cohort Study on Recurrence, Survival, and Quality of Life","volume":"58","author":"Xing","year":"2025","journal-title":"Curr. Probl. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Alexa, M., Hasenburg, A., and Battista, M.J. (2021). The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. Cancers, 13.","DOI":"10.3390\/cancers13061478"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kumari, A., Kumar, H., Harvey, S.E., Xing, D., and Li, Z. (2025). Molecular Classification of Endometrial Carcinomas: Review and Recent Updates. Cancers, 18.","DOI":"10.3390\/cancers18010051"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1633260","DOI":"10.3389\/fonc.2025.1633260","article-title":"POLE-Mutated Endometrial Cancer: New Perspectives on the Horizon?","volume":"15","author":"Fanale","year":"2025","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/tcmj.tcmj_120_24","article-title":"The Prognostic Implication of Polymerase Epsilon-Mutated Endometrial Cancer","volume":"37","author":"Wang","year":"2024","journal-title":"Tzu Chi Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hurmuz, I., Barna, R., Jurescu, A., Natar\u00e2\u0219, B., L\u0103zureanu, D.-C., Tr\u0103il\u0103, I.-A., Fur\u0103u, A.-M., T\u0103ban, S., and Dema, A. (2026). Prognostic Impact of POLE Exonuclease-Domain Mutations in Endometrial Cancer: A Systematic Review and Meta-Analysis. Cancers, 18.","DOI":"10.3390\/cancers18040597"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lian, M., Zhang, C., Li, T., and Wang, A. (2025). Immunotherapy in Endometrial Cancer: Mechanisms, Clinical Evidence, and Future Directions. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1697065"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Addante, F., d\u2019Amati, A., Santoro, A., Angelico, G., Inzani, F., Arciuolo, D., Travaglino, A., Raffone, A., D\u2019Alessandris, N., and Scaglione, G. (2024). Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021056"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Awosika, J.A., Gulley, J.L., and Pastor, D.M. (2025). Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094394"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jfma.2024.08.028","article-title":"A Comparative Analysis of MMR Immunohistochemistry Panels: Evaluating the Utility of Four-Protein versus Two-Protein Panels in Endometrial Cancer Patients","volume":"124","author":"Huang","year":"2025","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e009143","DOI":"10.1136\/jitc-2024-009143","article-title":"Immune Predictors of Response to Immune Checkpoint Inhibitors in Mismatch Repair-Deficient Endometrial Cancer","volume":"12","author":"Zeng","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.14309\/ajg.0000000000002132","article-title":"Screening for Lynch Syndrome: Optimal Strategies and Performance Remain a Moving Target","volume":"118","author":"Rustgi","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41379-022-01066-y","article-title":"Genomic Landscape of Endometrial Carcinomas of No Specific Molecular Profile","volume":"35","author":"Nguyen","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/PGP.0000000000001012","article-title":"P53 Abnormal (copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable from Serous Carcinoma","volume":"43","author":"Imboden","year":"2024","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"868","DOI":"10.5306\/wjco.v12.i10.868","article-title":"Human Epidermal Growth Factor Receptor 2 Targeted Therapy in Endometrial Cancer: Clinical and Pathological Perspectives","volume":"12","author":"Saito","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0090-8258(22)01309-9","article-title":"Molecular Classification of Endometrial Carcinomas: A Singleinstitution Review (084)","volume":"166","author":"Leitao","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"17588359211035959","DOI":"10.1177\/17588359211035959","article-title":"The Emerging Role of Molecular Pathology in Directing the Systemic Treatment of Endometrial Cancer","volume":"13","author":"Jamieson","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_51","first-page":"430","article-title":"Advancements in Cancer Immunotherapy: A Comprehensive Review of Immune Checkpoint Inhibitors with a Focus on Pembrolizumab and Emerging Strategies","volume":"2","author":"Peshin","year":"2024","journal-title":"Med. Clin. Case Rep. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cpt.2492","article-title":"Mechanistic Basis for Maximally Efficacious Dose of Pembrolizumab","volume":"111","author":"Mayawala","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41598-018-20325-0","article-title":"Inhibition of the Checkpoint Protein PD-1 by the Therapeutic Antibody Pembrolizumab Outlined by Quantum Chemistry","volume":"8","author":"Tavares","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.01.001","article-title":"Pembrolizumab\u2019s Non-Cross Resistance Mechanism of Action Successfully Overthrown Ipilimumab","volume":"111","author":"Wahid","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in Patients with Microsatellite Instability-High Advanced Endometrial Cancer: Results from the KEYNOTE-158 Study","volume":"40","author":"Bariani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S796","DOI":"10.1016\/j.annonc.2022.07.674","article-title":"546P Pembrolizumab for Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Endometrial Cancer: Long-Term Follow-up Results from KEYNOTE-158","volume":"33","author":"Bariani","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1080\/14796694.2025.2496133","article-title":"DOMENICA: Dostarlimab versus Chemotherapy Alone in First-Line MMR-Deficient Advanced Endometrial Cancer Patients","volume":"21","author":"Cherifi","year":"2025","journal-title":"Future Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: A Randomised, Double-Blind, Phase III Study of Pembrolizumab or Placebo plus Adjuvant Chemotherapy with or without Radiotherapy in Patients with Newly Diagnosed, High-Risk Endometrial Cancer","volume":"35","author":"Cibula","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus Carboplatin\/paclitaxel Followed by Maintenance Durvalumab with or without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of Polymerase E-Mutated and Microsatellite-Instable Endometrial Cancers with Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/EDBK_280503","article-title":"A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.18632\/oncotarget.23790","article-title":"Microsatellite Instability Is a Biomarker for Immune Checkpoint Inhibitors in Endometrial Cancer","volume":"9","author":"Yamashita","year":"2018","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3802\/jgo.2019.30.e46","article-title":"Immunotherapy in Endometrial Cancer: New Scenarios on the Horizon","volume":"30","author":"Capone","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"103306","DOI":"10.1016\/j.critrevonc.2021.103306","article-title":"Immune Checkpoint Inhibitors in Endometrial Cancer","volume":"161","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib Plus Pembrolizumab in Patients with Advanced Endometrial Cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_68","first-page":"23","article-title":"The Evolving Role of Immune Checkpoint Inhibitors in Cervical and Endometrial Cancer","volume":"7","author":"Colombo","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ijgo.70280","article-title":"Immune Checkpoint Inhibitors in Gynecologic Oncology: Current Status and Perspectives","volume":"171","author":"Yanaihara","year":"2025","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1158\/1078-0432.CCR-16-1031","article-title":"Regression of Chemotherapy-Resistant Polymerase \u03b5 (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab","volume":"22","author":"Santin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"17588359261423888","DOI":"10.1177\/17588359261423888","article-title":"Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Mismatch Repair-Deficient Endometrial Cancer","volume":"18","author":"Genestie","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The Role of Neoantigens and Tumor Mutational Burden in Cancer Immunotherapy: Advances, Mechanisms, and Perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/ijgc-2022-004026","article-title":"Mismatch Repair Deficiency, next-Generation Sequencing-Based Microsatellite Instability, and Tumor Mutational Burden as Predictive Biomarkers for Immune Checkpoint Inhibitor Effectiveness in Frontline Treatment of Advanced Stage Endometrial Cancer","volume":"33","author":"Hill","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"103851","DOI":"10.1016\/j.critrevonc.2022.103851","article-title":"Advanced and Recurrent Endometrial Cancer: State of the Art and Future Perspectives","volume":"180","author":"Tronconi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00404-024-07862-y","article-title":"Prognostic and Clinical Heterogeneity of PD1 and PD-L1- Immunohistochemical Scores in Endometrial Cancers","volume":"311","author":"Proppe","year":"2025","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Lu, L., Li, Y., Luo, R., Xu, J., Feng, J., and Wang, M. (2020). Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00632"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2021.07.009","article-title":"PD-L1 Expression in Tumor Cells Is Associated with a Favorable Prognosis in Patients with High-Risk Endometrial Cancer","volume":"162","author":"Zong","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer Immunoediting and Resistance to T Cell-Based Immunotherapy","volume":"16","author":"Teng","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive Biomarkers and Mechanisms Underlying Resistance to PD1\/PD-L1 Blockade Cancer Immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"18645","DOI":"10.1038\/s41598-025-02723-3","article-title":"Unraveling the Mechanisms of irAEs in Endometrial Cancer Immunotherapy: Insights from FAERS and scRNA-Seq Data","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.gore.2024.101351","article-title":"Cost Effectiveness of Immunotherapy Combination Therapies for Endometrial Cancer","volume":"52","author":"Benjamin","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.3802\/jgo.2025.36.e6","article-title":"Immunotherapy plus Chemotherapy in Patients with Advanced Endometrial Cancer: A Cost-Effectiveness Analysis","volume":"36","author":"Zhu","year":"2025","journal-title":"J. Gynecol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"210","DOI":"10.6004\/jnccn.2022.7096","article-title":"Molecular Profiling of Endometrial Cancer from TCGA to Clinical Practice","volume":"21","author":"Jamieson","year":"2023","journal-title":"Off. J. Natl. Compr. Cancer Netw."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1703\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:12:09Z","timestamp":1780632729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":85,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["diagnostics16111703"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16111703","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}